Guide
Clinical hold risk indicators are signals in an Investigational New Drug package that increase the chance the FDA will pause or limit the proposed study. They cluster across nonclinical, CMC, clinical protocol, starting-dose, and safety dimensions. Structured pre-submission review helps surface and address them before the IND is filed.
Clinical hold risk is the likelihood that an FDA reviewer will identify issues serious enough to pause or restrict the proposed clinical study. It is not a regulatory prediction — it is a structured way to think about gaps in the submission.
| Risk category | Example signals | Review focus |
|---|---|---|
| Nonclinical | Incomplete species coverage, short duration | Does the package support proposed dose and duration? |
| CMC | Limited stability, undefined impurity strategy | Is clinical material adequately controlled? |
| Protocol | Eligibility mismatched to safety profile | Does the design protect the proposed population? |
| Starting dose | No explicit safety factor or MABEL rationale | Is the rationale defensible and conservative? |
| Safety | Missing stopping rules, no DSMB plan if expected | Are stopping and pause criteria explicit? |
Risk signals are surfaced by structured review of the package against the same dimensions reviewers commonly probe. AI-assisted readiness workflows can help by comparing the proposed plan against typical expectations and flagging gaps for expert review.
Clinical hold risk refers to signals in an IND package that increase the likelihood the FDA will pause or limit a proposed clinical study after submission. Typical signals span nonclinical, CMC, protocol, starting-dose, and safety dimensions.
They are identified by structured review of the IND package against the dimensions FDA reviewers commonly examine, comparing the proposed plan against typical expectations and surfacing gaps that would likely generate questions.
Not entirely. The goal is to identify and reduce avoidable risk signals before submission so the remaining questions are program-specific rather than gaps in documentation, evidence, or rationale.
Request an IND readiness assessment connected to Alenvo.
Check IND Readiness